Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue in SARS-CoV-2 infection
NCT04635605Phase 2Completed
- Sponsor
- Fondazione Epatocentro Ticino
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of methylene blue in coronavirus disease 2019 (COVID-19), sponsored by Fondazione Epatocentro Ticino. Primary endpoint: Viral load kinetics AUC 0-21 at 21 days. Started Nov 2020; status: completed.
02
Drugs
methylene blue
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04635605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635605.